Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
Public ClinicalTrials.gov record NCT01498874. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Gevokizumab in Subjects With Moderate to Severe Acne Vulgaris
Study identification
- NCT ID
- NCT01498874
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- XOMA (US) LLC
- Industry
- Enrollment
- 127 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- gevokizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 17 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2011
- Primary completion
- Mar 31, 2013
- Completion
- May 31, 2013
- Last update posted
- Mar 3, 2014
2011 – 2013
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Hot Springs | Arkansas | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Bay City | Michigan | — | — |
| Not listed | Fridley | Minnesota | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | High Point | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | South Euclid | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Arlington | Texas | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01498874, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 3, 2014 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01498874 live on ClinicalTrials.gov.